West Pharmaceutical stock gains after raised 2026 guidance and strong Q2 figures

Published on 09/17/2026 at 15:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical stock closed at USD 365.00 on the New York Stock Exchange on September 15, 2026, up 2.76 percent after strong recent quarterly figures. The company lifted its full-year 2026 guidance, now targeting up to USD 3.380 billion in net sales and adjusted EPS as high as USD 9.05.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012 — West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical Services, Inc. stock (ISIN US9523901012) ended the September 15, 2026 session at USD 365.00 on the New York Stock Exchange, marking a 2.76 percent gain versus the prior close as investors responded to robust recent quarterly results and a higher full-year outlook.

Raised 2026 guidance supports the shares

According to Stock Titan on September 16, 2026, West Pharmaceutical raised its full-year 2026 guidance to net sales between USD 3.345 billion and USD 3.380 billion, compared with an earlier range that implied USD 3.215 billion to USD 3.275 billion.

In the same update, the company guided for adjusted diluted EPS in fiscal 2026 of USD 8.85 to USD 9.05, up from a prior range of USD 7.85 to USD 8.20, signaling expected year-over-year growth of 7.7 percent to 12.5 percent in earnings per share.

For the third quarter of 2026, West Pharmaceutical now expects net sales between USD 820 million and USD 835 million and adjusted diluted EPS of USD 2.14 to USD 2.24, giving investors a concrete benchmark for near-term performance per Stock Titan.

Q2 2026 results show double-digit growth

West Pharmaceutical reported second-quarter 2026 net sales of USD 872.3 million, representing a 13.8 percent increase compared with the prior-year quarter and organic growth of 12.7 percent, as summarized by Stock Titan.

Diluted EPS in Q2 2026 was USD 2.15, up 18.1 percent year over year, while adjusted diluted EPS rose 28.8 percent to USD 2.37, reflecting both higher volumes and margin expansion according to Stock Titan.

Gross margin improved to 37.7 percent in Q2 2026 and adjusted operating margin reached 22.6 percent, demonstrating operating leverage as sales grew, based on data cited by Stock Titan.

For the first half of 2026, West Pharmaceutical generated operating cash flow of USD 213.9 million and free cash flow of USD 128.0 million after capital expenditures of USD 85.9 million, providing financial flexibility for shareholder returns and investment per Stock Titan.

Capital returns and outlook

West Pharmaceutical repurchased approximately 1.8 million shares for USD 454.3 million in the first half of 2026 and declared a quarterly dividend of USD 0.22 per share, underscoring a balanced approach to capital allocation that combines buybacks with cash distributions to shareholders according to Stock Titan.

Earlier in the year, West Pharmaceutical had already reported a strong first quarter of 2026, with net sales of USD 844.9 million, up 21.0 percent from the prior-year quarter, and organic growth of 15.3 percent, as noted by Stock Titan.

Diluted EPS in Q1 2026 rose to USD 1.92, a 56.1 percent increase year over year, while adjusted diluted EPS climbed 46.9 percent to USD 2.13, again supported by margin improvement, according to the same Stock Titan summary.

Stock level after the recent move

West Pharmaceutical stock closed at USD 365.00 on the New York Stock Exchange on September 15, 2026, up 2.76 percent from the prior session, with an intraday trading range between USD 354.65 and USD 370.67 and volume of about 981,890 shares, per NYSE data cited in a recent market wrap.